SEC Form 4 · accession 0001209191-18-027898
NEUROCRINE BIOSCIENCES INC · NBIX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Richard F Pops
Director
Period of report
May 1, 2018
Accepted (ET)
May 3, 2018 · 7:42 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000914475
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | May 1, 2018 | M | 15,000 | $7.05 | A | 44,512 | D | |
| Common StockF1 | May 1, 2018 | F | 1,253 | $84.39 | D | 43,259 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option | $7.05 | May 1, 2018 | M | 15,000 | A | Jun 25, 2011 | May 25, 2018 | Common Stock | 15,000 | 0 | D |
Explanation of responses
- F1The share issuance reported on Table I reflects shares issued upon the exercise of options granted on May 25, 2011, which, if unexercised would have expired on May 25, 2018. The option exercises are reported on Table II. These option exercises were pursuant to a net issuance arrangement effected under the Issuer's 2003 Equity Incentive Plan, as amended. The number of shares issued pursuant to the net issuance arrangement was calculated as follows: the option exercise price ($7.05) was subtracted from the May 01, 2018 market close price ($84.39), and this net amount ($77.34) was then multiplied by the number of options (15,000), with the resulting amount then divided by the market close price to result in a net issuance of 13,747 shares to the optionee. The 1,253 shares underlying the remaining portion of the options are not available for re-issuance, and no shares were sold into the market as a part of the exercise in connection with a net issuance program.